Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis
Clinical Rheumatology, 03/11/2011
Alexeeva EI et al. – Treatment of severe juvenile idiopathic arthritis (JIA) represents a serious challenge. This study investigates the efficacy and safety of repeat courses of rituximab in patients with different forms of JIA refractory to infliximab and standard immunosuppressive therapy.